DDR2 and cancer: Based on the overall data, we would like to conclude that the DDR2 gene mutation is detectable in the CNS metastases of NSCLC, and analysis of gene profile in cancer patients may extend the scope of molecularly targeted therapies used both in patients with primary and metastatic NSCLC.